Bastani J B, Troester M M, Bastani A J
Dept. of Psychiatry, Bryan Memorial Hospital, Lincoln, NE 68506, USA.
Nebr Med J. 1996 Apr;81(4):107-9.
To report a serotonin syndrome reaction in a patient taking fluvoxamine to replace an earlier SSRI agent.
A female patient with Obsessive Compulsive Disorder on paroxetine after resurgence in her obsessive ruminations was started on fluvoxamine 50 mg daily. One week later she became suicidal and was hospitalized. The fluvoxamine was increased to 50 mg morning and 100 mg bedtime and the paroxetine was discontinued. Over the next few days she began to have trouble with her concentration. A low grade fever set in after she experienced auditory hallucinations. Fluvoxamine was discontinued and she had an uneventful recovery after twenty-four hours.
Fluvoxamine is a recently approved serotonin selective reuptake inhibitor (SSRI) with few side effect profiles. It is effective in the treatment of Depressive Disorder and Obsessive Compulsive Disorder and is used to potentiate or replace other anti-OCD drugs including already available serotonin specific reuptake inhibitors (SSRI). We wish to draw attention to the potential for serotonin syndrome in patients on fluvoxamine who may have previously been on other SSRIs.
报告1例服用氟伏沙明替代早期5-羟色胺再摄取抑制剂（SSRI）药物时发生的血清素综合征反应。
1例患有强迫症的女性患者，在强迫性沉思复发后服用帕罗西汀，开始每日服用50mg氟伏沙明。1周后，她出现自杀倾向并住院治疗。氟伏沙明剂量增加至早上50mg、睡前100mg，并停用帕罗西汀。在接下来的几天里，她开始出现注意力不集中的问题。在出现幻听后，她开始低热。停用氟伏沙明后，24小时内她顺利康复。
氟伏沙明是最近获批的5-羟色胺再摄取抑制剂（SSRI），副作用较少。它在治疗抑郁症和强迫症方面有效，可用于增强或替代其他抗强迫症药物，包括已有的5-羟色胺特异性再摄取抑制剂（SSRI）。我们希望引起人们对服用氟伏沙明的患者（这些患者之前可能服用过其他SSRI）发生血清素综合征可能性的关注。
